Monday, December 19, 2016

BRIEF-Sarepta Therapeutics announces EMA validation of Eteplirsen

* Sarepta Therapeutics announces EMA validation of

Eteplirsen authorization application for treatment of Duchenne

muscular Dystrophy amenable to exon skipping 51

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)